Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia

Imagem de Miniatura
Arquivos
art_BEN-OMRAN_RealWorld_Outcomes_with_Lomitapide_Use_in_Paediatric_Patients_2019.PDF (1.88 MB)
Citações na Scopus
33
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
BEN-OMRAN, Tawfeg
MASANA, Luis
KOLOVOU, Genovefa
ARICETA, Gema
NOVOA, F. Javier
LUND, Allan M.
BOGSRUD, Martin P.
ARAUJO, Maria
HUSSEIN, Osamah
IBARRETXE, Daiana
Citação
ADVANCES IN THERAPY, v.36, n.7, p.1786-1811, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IntroductionHomozygous familial hypercholesterolaemia (HoFH) is a rare, autosomal disease affecting the clearance of low-density lipoprotein cholesterol (LDL-C) from circulation, and leading to early-onset atherosclerotic cardiovascular disease (ASCVD). Treatment consists mainly of statins, lipoprotein apheresis (LA) and, more recently, the microsomal triglyceride transfer protein inhibitor lomitapide. Lomitapide is not licensed for use in children, but has been made available through an expanded access programme or on a named patient basis.MethodsThis case series includes 11 HoFH patients in 10 different centres in eight countries, less than 18years of age (mean 11.61.1years, 64% male), with signs of ASCVD, and who have received treatment with lomitapide (mean dose 24.54.3mg/day; mean exposure 20.02.9months). Background lipid-lowering therapy was given according to local protocols. Lomitapide was commenced with a stepwise dose escalation from 2.5mg or 5mg/day; dietary advice and vitamin supplements were provided as per the product label for adults. Laboratory analysis was conducted as part of regular clinical care.Results In the 11 cases, mean baseline LDL-C was 419 +/- 74.6mg/dL and was markedly reduced by lomitapide to a nadir of 176.7 +/- 46.3mg/dL (58.4 +/- 6.8% decrease). Six patients achieved recommended target levels for children below 135mg/dL, five of whom had LA frequency reduced. In one case, LDL-C levels were close to target when lomitapide was started but remained stable despite 75% reduction in LA frequency (from twice weekly to biweekly). Adverse events were mainly gastrointestinal in nature, occurred early in the treatment course and were well managed. Three patients with excursions in liver function tests were managed chiefly without intervention; two patients had decreases in lomitapide dose.Conclusions Lomitapide demonstrated promising effectiveness in paediatric HoFH patients. Adverse events were manageable, and the clinical profile of the drug is apparently similar to that in adult patients.Funding Amryt Pharma.
Palavras-chave
Adverse events, Atherosclerosis, Cardiology, Homozygous familial hypercholesterolaemia, Lipidology, Lomitapide, Low-density lipoprotein cholesterol, Paediatric, Real-world data, Patient cases
URI
https://observatorio.fm.usp.br/handle/OPI/33056
Referências
  1. Aegerion Pharmaceuticals Inc, 2013, JUXT PRESCR INF 2013
  2. Amryt Pharmaceuticals DAC, 2017, LOJ SUMM PROD CHAR 2
  3. Averna M, 2016, NUTR METAB CARDIOVAS, V26, P36, DOI 10.1016/j.numecd.2015.11.001
  4. Blom DJ, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0841-3
  5. Blom DJ, 2017, CIRCULATION, V136, P332, DOI 10.1161/CIRCULATIONAHA.117.028208
  6. Bruckert E, 2014, ATHEROSCLEROSIS SUPP, V15, P46, DOI 10.1016/j.atherosclerosissup.2014.07.006
  7. Chacra AP, 2019, J CLIN LIPIDOL
  8. Cuchel M, 2013, AM HEART ASS SCI SES
  9. Cuchel M, 2014, EUR HEART J, V35, P2146, DOI 10.1093/eurheartj/ehu274
  10. Cuchel M, 2013, LANCET, V381, P40, DOI 10.1016/S0140-6736(12)61731-0
  11. D'Erasmo L, 2017, ADV THER, V34, P1200, DOI 10.1007/s12325-017-0531-x
  12. Gagne C, 2002, CIRCULATION, V105, P2469, DOI 10.1161/01.CIR.0000018744.58460.62
  13. Horton JD, 2009, J LIPID RES, V50, pS172, DOI 10.1194/jlr.R800091-JLR200
  14. Hudgins LC, 2008, AM J CARDIOL, V102, P1199, DOI 10.1016/j.amjcard.2008.06.049
  15. Humphries SE, 2018, J CLIN LIPIDOL, V12, P25, DOI 10.1016/j.jacl.2017.11.005
  16. Kroon AA, 2000, ATHEROSCLEROSIS, V152, P519, DOI 10.1016/S0021-9150(00)00371-3
  17. Leipold R, 2017, EUR J PREV CARDIOL, V24, P1843, DOI 10.1177/2047487317730473
  18. Luirink IK, 2018, J CLIN LIPIDOL
  19. Moriarty PM, 2016, EUR HEART J
  20. Nordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273
  21. Raal FJ, 2017, LANCET DIABETES ENDO
  22. Real JArbonaCGoterrisRAscasoJF, 2018, BMJ CASE REP 2018, V2018
  23. Santos RD, 2016, LANCET DIABETES ENDO, V4, P850, DOI 10.1016/S2213-8587(16)30041-9
  24. Stefanutti C, 2001, ACTA PAEDIATR, V90, P694, DOI 10.1080/080352501750258793
  25. Thompson GR, 2010, CURR OPIN LIPIDOL, V21, P492, DOI 10.1097/MOL.0b013e3283402f53
  26. Thompson GR, 2010, ATHEROSCLEROSIS, V208, P317, DOI 10.1016/j.atherosclerosis.2009.06.010
  27. Underberg J, 2018, ACC18 67 ANN SCI SES
  28. van Lennep JR, 2015, J CLIN LIPIDOL, V9, P607, DOI 10.1016/j.jacl.2015.05.001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03